Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000733915 | SCV000862020 | uncertain significance | not provided | 2018-07-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001086227 | SCV001001505 | benign | Homocystinuria due to methylene tetrahydrofolate reductase deficiency | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Pars Genome Lab | RCV001086227 | SCV001652883 | likely benign | Homocystinuria due to methylene tetrahydrofolate reductase deficiency | 2021-05-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002411180 | SCV002716751 | likely benign | Inborn genetic diseases | 2022-05-24 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Natera, |
RCV001086227 | SCV001459041 | likely benign | Homocystinuria due to methylene tetrahydrofolate reductase deficiency | 2019-11-11 | no assertion criteria provided | clinical testing | |
Genome Diagnostics Laboratory, |
RCV000733915 | SCV001931064 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000733915 | SCV001972510 | likely benign | not provided | no assertion criteria provided | clinical testing |